Researchers led by Jorge Maese-Calvo of Fundación COMPUTAEX, together with clinicians and investigators across Spain’s Extremadura region, have developed an interpretable machine learning approach that predicts whether an individual heart failure patient will be readmitted within 30 days of discharge. Their work, published in Medical & Biological Engineering & Computing, draws on a remarkable asset: a population-based registry covering two decades of heart failure hospitalizations in a rural Spanish healthcare setting. The registry, spanning the years 2000 to 2019, includes nearly 5,000 admissions and had never before been used for artificial intelligence modeling, making it a uniquely grounded testing ground for predictive algorithms in an underserved population.

The scale of the problem the team tackled is hard to overstate. Heart failure affects an estimated 64 million people worldwide, and its prevalence continues to climb as populations age. In the Spanish cohort studied, 8.2 percent of patients were readmitted within 30 days of discharge. While that figure may sound modest, each readmission represents a clinical setback for the patient, a financial burden for the health system, and a missed opportunity for the kind of targeted post-discharge support that could have kept the person at home. Hospital systems in the United States and Europe have introduced penalty and incentive programs around readmission rates, but risk stratification at the moment of discharge remains crude, often relying on clinicians’ intuition or simple scoring rules that capture only part of the picture.

The researchers’ strategy was deliberately pragmatic. Rather than demanding exotic biomarkers or data types that rural hospitals cannot easily collect, they built their models from routinely gathered clinical variables: demographic details, laboratory values, comorbidities, admission characteristics, and length of stay. Three machine learning algorithms were trained and compared against conventional binary logistic regression, the statistical workhorse that has historically served as the default for clinical risk prediction. The contenders were a random forest, an ensemble method that aggregates hundreds of decision trees; extreme gradient boosting, known as XGBoost, which builds trees sequentially to correct earlier errors; and a support vector machine, which finds optimal boundaries separating patient groups in high-dimensional space.

The results were clear. The random forest model emerged as the strongest performer, achieving an area under the receiver operating characteristic curve, or AUC, of 0.812, with a 95 percent confidence interval of 0.744 to 0.867. An AUC of 0.5 indicates performance no better than a coin flip, while 1.0 represents perfect discrimination; a value above 0.80 reflects clinically useful discrimination. By contrast, binary logistic regression managed an AUC of 0.686, with a confidence interval of 0.617 to 0.755. The gap matters because clinical prediction is unforgiving: a model that merely matches traditional statistics offers no reason to change practice, but a model that meaningfully outperforms it can reshape how discharge decisions are made. The advantage of tree-based ensembles lies in their ability to capture nonlinear relationships and interactions between variables, such as the way renal dysfunction may amplify risk differently depending on a patient’s age or prior cardiac history, relationships that rigid regression forms can miss.

What distinguishes this study from many AI-in-medicine efforts is its insistence on interpretability. Black-box models have faced justified skepticism from clinicians who need to understand why an algorithm flags a particular patient as high risk before acting on that information. To open the box, the team applied SHAP, or SHapley Additive exPlanations, a technique borrowed from cooperative game theory that assigns each predictor a quantified contribution to every individual prediction. SHAP values reveal not only which variables matter most overall but also the direction and consistency of their effects, exposing whether, for instance, longer hospital stays push risk up or down across the cohort or whether the relationship shifts in different patient subgroups. This transparency, the authors argue, is what transforms a prediction from an oracle’s pronouncement into a clinical instrument.

The SHAP analysis identified a compact set of dominant predictors. The period in which the patient was admitted emerged as influential, reflecting how the clinical profile and outcomes of heart failure hospitalizations evolved across the two decades covered by the registry, as treatment practices and diagnostic standards changed. Markers of renal dysfunction ranked among the strongest signals, consistent with a growing body of evidence linking impaired kidney function to heart failure readmissions; the cardiorenal interplay means that failing kidneys often herald decompensating hearts. A history of prior heart failure, older age, and longer length of hospital stay completed the top tier of predictors. Each of these is available to clinicians before discharge, which means the model’s inputs place no new burden on resource-constrained rural facilities.

The implications reach beyond the algorithm’s raw performance. In rural health systems, where access to cardiologists, structured follow-up clinics, and home-monitoring programs is often limited, every intervention dollar must be spent where it counts. A transparent risk score computed at discharge could direct scarce resources, such as early nurse visits, telemonitoring enrollment, or expedited outpatient appointments, toward the patients most likely to return. Because the model explains itself, a hospitalist in a small regional hospital could see that a particular patient’s risk is driven chiefly by declining renal markers and a prior heart failure admission, and tailor the discharge plan accordingly. The study was supported by Spain’s Ministry of Science and Innovation through the Complementary Plan for Applied Biotechnology in Health, backed by Next Generation EU funds, reflecting a broader European push to bring precision medicine tools into everyday care.

The authors are careful about what their results do and do not establish. The model was trained and validated within a single regional registry, and its performance in other populations, health systems, and countries remains to be demonstrated. External validation in independent cohorts and prospective evaluation of real-world impact, measuring whether the model actually reduces readmissions when deployed at the bedside, are required before clinical implementation. The underlying data are not publicly available due to privacy and ethical restrictions, though access may be considered with appropriate approvals. These caveats are standard in the field, and the study’s methodology aligns with emerging international guidance such as the TRIPOD+AI reporting framework and the FUTURE-AI consensus on trustworthy clinical artificial intelligence, both of which emphasize rigorous validation, transparency, and fairness. Even with those limitations, the work represents a meaningful step forward. It demonstrates that interpretable machine learning, fed by the ordinary data that any hospital already collects, can outperform traditional statistical models and deliver predictions clinicians can actually understand. For rural communities bearing a disproportionate share of the heart failure burden, that combination of accuracy, accessibility, and transparency could prove decisive in keeping vulnerable patients from cycling back through hospital doors.

Subject of Research: Interpretable machine learning prediction of 30-day readmission after heart failure hospitalization using a 20-year rural population registry

Article Title: Predicting 30-day readmission after heart failure hospitalization using interpretable machine learning: evidence from a 20-year population-based rural registry

Article References: Maese-Calvo, J., Paredes-Calderón, A., Nunez-Bayon, M., Arévalo-Lorido, J. C., Mayoral-Testón, N., Nevado-Nogales, C., José Zaro-Bastanzuri, M., González-Fernández, R., Hernández-Rollán, N., Corral-García, J., Rico-Gallego, J. A., & Fernández-Bergés, D. (2026). Predicting 30-day readmission after heart failure hospitalization using interpretable machine learning: evidence from a 20-year population-based rural registry. Medical & Biological Engineering & Computing. https://doi.org/10.1007/s11517-026-03657-2

Image Credits: AI Generated

DOI: 10.1007/s11517-026-03657-2

Keywords: heart failure, hospital readmission, machine learning, random forest, XGBoost, SHAP, interpretable AI, rural health, renal dysfunction, clinical decision support, risk prediction, registry study